Insmed/$INSM
1D1W1MYTD1Y5YMAX
Capital at risk
About Insmed
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
- Ticker
- $INSM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,664
- Headquarters
- Bridgewater, United States
- Website
- www.insmed.com
Insmed Metrics
BasicAdvanced
$28B
-
-$4.08
0.79
-
Price and volume
Market cap
$28B
Beta
0.79
52-week high
$212.75
52-week low
$90.39
Average daily volume
2.7M
Financial strength
Current ratio
3.724
Quick ratio
3.135
Long term debt to equity
96.358
Total debt to equity
97.654
Interest coverage (TTM)
-9.99%
Profitability
EBITDA (TTM)
-794.955
Gross margin (TTM)
83.46%
Net profit margin (TTM)
-76.94%
Operating margin (TTM)
-71.43%
Effective tax rate (TTM)
-0.71%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
-22.17%
Return on equity (TTM)
-87.22%
Valuation
Price to revenue (TTM)
23.831
Price to book
36.39
Price to tangible book (TTM)
52.22
Price to free cash flow (TTM)
-31.795
Free cash flow yield (TTM)
-3.15%
Free cash flow per share (TTM)
-3.972
Growth
Revenue change (TTM)
185.76%
Earnings per share change (TTM)
-28.60%
3-year revenue growth (CAGR)
61.62%
3-year earnings per share growth (CAGR)
-8.18%
10-year earnings per share growth (CAGR)
6.68%
What the Analysts think about Insmed
Analyst ratings (Buy, Hold, Sell) for Insmed stock.
Analyst projections of the future price of Insmed stock.
Bulls say / Bears say
Insmed's Q2 2026 product revenues of $425.5 million topped consensus by ~$30 million, fueled by BRINSUPRI's $309.2 million (+49% sequential growth) and ARIKAYCE's $116.3 million (+8% year-over-year) (PR Newswire, MarketBeat).
Management raised full-year 2026 BRINSUPRI revenue guidance to $1.25 billion–$1.40 billion (from at least $1 billion) and reiterated ARIKAYCE guidance of $450 million–$470 million, reflecting confidence in commercial momentum (PR Newswire).
In July 2026, Insmed reported positive 12-month open-label extension data for TPIP in PAH patients, demonstrating sustained improvement in 6-minute walk distance, NT-proBNP levels, and REVEAL Lite 2.0 risk scores, strengthening the Phase 3 program’s outlook (MarketScreener).
Despite topline growth, Insmed recorded a net loss of $13.2 million (−$0.06 per share) in Q2 2026, underscoring ongoing unprofitability and reliance on external funding (PR Newswire).
Revenue concentration in two products—BRINSUPRI and ARIKAYCE accounted for 100% of Q2 2026 revenues—exposes Insmed to competitive, regulatory, and market-access risks in a narrow commercial portfolio (PR Newswire).
High operating expenses—R&D of $210 million and SG&A of $247.5 million in Q2 2026—coupled with a cash burn trajectory, may pressure margins and necessitate future equity or debt financing despite a $1.2 billion cash balance (PR Newswire).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Insmed Financial Performance
Revenues and expenses
Insmed Earnings Performance
Company profitability
Upcoming events
No upcoming events
Insmed News
AllArticlesVideos
Funds containing Insmed
AllUSDGBPEUR
Fund name | Fund size | $INSM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.58% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.58% |
Amundi S&P 500£500G | £6.6B | 0.86% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.12% |
iShares MSCI USA ESG Enhanced€OM3L | €16B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.